



Date: 6th March, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
BSE Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Sub: Alembic Pharmaceuticals Reports First Prescription Sale of Pivya® (pivmecillinam) Following US Commercial Launch through Alembic Therapeutics LLC

Dear Sir/Madam,

We are pleased to inform the Exchange that Alembic Therapeutics LLC, a step-down wholly owned subsidiary of Alembic Pharmaceuticals Limited, has reported its first prescription-based sale in the United States of America (US) following the commercial launch of **Pivya® (pivmecillinam) tablets**, an oral prescription antibiotic.

Please find enclosed herewith our press release for your reference.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,

For **Alembic Pharmaceuticals Limited**

Manisha Saraf

Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123



PRESS RELEASE

6 March 2026 | Vadodara, India

Alembic Pharmaceuticals Reports First Prescription Sale of Pivya® (pivmecillinam) Following US Commercial Launch

Alembic Pharmaceuticals Limited (“Alembic”) today announced the first prescription-based sale of **Pivya® (pivmecillinam) tablets**, an oral prescription antibiotic, following its recent commercial launch in the United States of America (US). Pivya® is Alembic’s first branded pharmaceutical product in the US and is being marketed through Alembic Therapeutics LLC, a step-down wholly owned subsidiary of Alembic.

Pivya® represents a first-line oral antibiotic option for the treatment of uncomplicated urinary tract infections (uUTIs) in women. The segment has seen limited new product introductions for more than a decade, creating an opportunity for a clinically established therapy with a strong safety and efficacy profile.

Commenting on the milestone, **Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited**, said:

“The commercial launch of Pivya® marks an important milestone for Alembic as we enter the US branded pharmaceuticals market. What began as a strategic acquisition has now translated into a commercial presence in the specialty prescription segment.

Pivya® represents the first step in Alembic’s strategy to build a focused branded specialty portfolio in the US, enabling us to participate in a large and stable therapeutic category with a clinically established and differentiated product. Over time, we intend to leverage this platform to build a broader branded portfolio in the US market.”

Market Context

Uncomplicated urinary tract infections remain among the most common bacterial infections in women in the US, resulting in a significant volume of outpatient antibiotic prescriptions annually. With increasing emphasis on appropriate antibiotic stewardship and the need for effective first-line therapies, clinically established agents such as pivmecillinam are expected to play an important role in the management of uncomplicated urinary tract infections.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123



The therapeutic category represents a large and stable market, accounting for approximately 30 million prescriptions annually in the US.

About Pivya® (pivmecillinam)

Pivya® contains pivmecillinam, a beta-lactam antibacterial agent with a long history of clinical use internationally. Pivya® is a penicillin-class antibacterial indicated for the treatment of female patients (18 years of age and older) with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Pivya® and other antibacterial drugs, Pivya® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Commercial Strategy:

Alembic has established an initial sales footprint across key territories in the US, with each territory focusing on high-prescribing physicians in women's health and engaging a targeted base of prescribers.

The Company plans a phased expansion of field force as prescription momentum builds, supported by targeted physician education and market access initiatives.

Strategic Context:

Alembic continues to expand its presence in the US, one of the world's largest pharmaceutical markets, through a balanced approach across generics, specialty products, and branded pharmaceuticals. The launch of Pivya® represents an important step in building a focused branded business platform in the US, complementing the Company's established generics franchise.

Alembic remains committed to disciplined investments that support sustainable growth and long-term value creation.

About Alembic Therapeutics LLC

Alembic Therapeutics LLC is committed to providing high-quality prescription medicines to support patient care and healthcare delivery. The launch of Pivya® reflects our ongoing focus on Quality, Reliability, and Access.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123



About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Its brands, marketed through a field force of over 5500+, are well recognized by doctors and patients.

Information about the Company can be found at www.alembicpharmaceuticals.com;
(Reuters:ALEM.NS) (Bloomberg:ALPM) (NSE:APLLTD) (BSE:533573)

For more information, contact:

Ajay Kumar Desai

Phone: +91 22-66953681

Email: ajay.desai@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123